click below
click below
Normal Size Small Size show me how
Oncology Exam 1 Drug
| Drug | Target | |||
|---|---|---|---|---|
| Gefitinib | EGFR | |||
| Cetuximab | EGFR | |||
| Panitumumab | EGFR | |||
| Osimertinib | EGFR + variants | |||
| Lapatinib | EGFR, HER2 | |||
| Afatinib | EGFR, HER2, HER4 | |||
| Tucatinib | HER2 | |||
| Trastuzumab | HER2 | |||
| ado-trastuzumab | HER2 | |||
| fam-trastuzumab | HER2 | |||
| Pertuzumab | HER2 | |||
| Lorlatinib | ALK, ROS1 | |||
| Crizotinib | ALK, ROS1, MET | |||
| Ensartinib | ALK, ROS1, MET | |||
| Brigatinib | ALK, ROS1, FLT3, vEGFR | |||
| Alectinib | ALK, RET | |||
| Midostaurin | FLT3, ITD/TKD variants | |||
| Quizartinib | FLT3, ITD variant | |||
| Larotrectinib | TRKA, TRKB, TRKC | |||
| Repotrectinib | TRKA, TRKB, TRKC, ROS1 | |||
| Entrectinib | TRKA, TRKB, TRKC, ROS1, ALK | |||
| Pralsetinib | wild-type/mutated RET | |||
| Selpercatinib | wild-type/mutated RET, VEGFRs, FGFRs | |||
| Capmatinib | MET | |||
| Tepotinib | MET | |||
| Amivantamab-vmjw | EGFR, MET | |||
| Acalabrutinib | BTK | |||
| Zanabrutinib | BTK | |||
| Imatinib | ABL (+BCR-ABL), PDGFR, KIT | |||
| Dasatinib | BCR-ABL (variants), Src | |||
| Nilotinib | wild-type BCR-ABL | |||
| Bosutinib | BCR-ABL, Src | |||
| Ponatinib | BCR-ABL | |||
| Asciminib | ABL | |||
| Dabrafenib | BRAF variants | |||
| Encorafenib | BRAF variants, other kinases | |||
| Trametinib | MEK1, MEK2, BRAF V600E | |||
| Binimetinib | MEK1, MEK2, BRAF V600E | |||
| Palbociclib | CDK4, CDK6 | |||
| Ribociclib | CDK4, CDK6 | |||
| Abemaciclib | CDK4, CDK6 | |||
| Bevacizumab | VEGF-A | |||
| Thalidomide | VEGF-A | |||
| Lenalidomide | VEGF-A | |||
| Nivolumab | PD-1 | |||
| Pembrolizumab | PD-1 | |||
| Cemiplimab-rwlc | PD-1 | |||
| Atezolizumab | PD-L1 | |||
| Durvalumab | PD-L1 | |||
| Rituximab | CD20 | |||
| Obinutuzumab | CD20 | |||
| Blinatumomab | CD19, CD3 | |||
| Venetoclax | BCL-2 | |||
| E.coli Pegaspargase Erwinia | L-asparagine |